Processa secures strategic investment, evaluates crypto strategy

Processa Pharmaceuticals (PCSA) announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives. The company said, “We believe that strategic engagement with emerging financial technologies, including select cryptocurrencies with potential yield-generating capabilities, may offer novel avenues to diversify our capital base and enhance financial flexibility, while providing an opportunity for long-term value creation. While we remain committed to rigorous compliance with all applicable regulatory standards, we recognize the potential for blockchain-based assets to contribute meaningfully to the funding of our clinical development programs. This approach could allow us to reduce dilution for existing shareholders, access additional sources of capital, and position the company at the forefront of biotech-fintech convergence.”